Pixl Bio

East of England

Founded 2025

Human iPSC models and AI phenomics for drug discovery

Pixl Bio combines human induced pluripotent stem cell (iPSC) models with AI-driven image analysis for drug discovery and safety research.

Its portfolio includes liver cells, stellate cells and disease models, alongside CRISPR engineering, high-content Cell Painting and contract studies. These tools help researchers investigate disease mechanisms, drug responses and toxicity.

Formed from DefiniGEN and Sweden's Phenaros in 2025, the company retains laboratory operations at Babraham Research Campus.

Reagents & Consumables CRO Drug Discovery Cell Culture Imaging & Microscopy

Metabolic Disease Rare Diseases Gene Editing

Is this your company?

Claim this page to receive a verified badge and keep your profile up to date.

Claim page

Company Notes

Previously Known As

DefiniGEN

AKA / Aliases

Definigen, DefiniGEN

Member of

Babraham Research Campus

Similar Companies